Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  241 results for ""Sodium-Glucose Transporter 2 Inhibitors""

Your Filters

Publisher : oxford university press
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study.

  • Authors : Engström A; Clinical Epidemiology Division, Department of Medicine, Karolinska Institutet, Solna, Stockholm 171 77, Sweden.; Söderling J

Subjects: Glucosides*/Glucosides*/Glucosides*/adverse effects ; Glucosides*/Glucosides*/Glucosides*/therapeutic use ; Benzhydryl Compounds*/Benzhydryl Compounds*/Benzhydryl Compounds*/adverse effects

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Aug 14; Vol. 10 (5), pp. 432-443.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.

  • Authors : Eroglu TE; Amsterdam UMC, Academic Medical Center, University of Amsterdam, Department of Experimental and Clinical Cardiology, Heart Centre, Amsterdam Cardiovascular Sciences, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.; Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Gentofte Hospitalsvej 6, PO Box 635, DK-2900 Hellerup, Denmark.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Jul 16; Vol. 10 (4), pp. 289-295.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis.

  • Authors : Theodorakopoulou MP; First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki GR54642, Greece.; Alexandrou ME

Subjects: Glomerular Filtration Rate*/Glomerular Filtration Rate*/Glomerular Filtration Rate*/drug effects ; Heart Failure*/Heart Failure*/Heart Failure*/diagnosis ; Heart Failure*/Heart Failure*/Heart Failure*/epidemiology

  • Source: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2024 Jul 16; Vol. 10 (4), pp. 329-341.Publisher: Oxford University Press Country of Publication: England NLM ID: 101669491 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-glucose cotransporter-2 inhibitors in diabetes and inflammatory skin diseases.

  • Authors : Shen CH; Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Chang Gung Memorial Hospital Linkou Medical Center, Taoyuan, Taiwan.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Humans

  • Source: The British journal of dermatology [Br J Dermatol] 2024 Aug 14; Vol. 191 (3), pp. 467-468.Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

  • Authors : Ostrominski JW; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA.; Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Heart Failure*/Heart Failure*/Heart Failure*/drug therapy ; Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/Glucagon-Like Peptide-1 Receptor*/agonists

  • Source: European heart journal [Eur Heart J] 2024 Aug 09; Vol. 45 (30), pp. 2748-2751.Publisher: Oxford University Press Country of Publication: England NLM ID: 8006263 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Weekly Journal Scan: sodium/glucose cotransporter 2 inhibition after myocardial infarction still in the grey area.

  • Authors : Liuzzo G; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo A. Gemelli 8, 00168 Rome, Italy.; Department of Cardiovascular and Pulmonary Sciences, Catholic University School of Medicine, Largo F. Vito 1, 00168 Rome, Italy.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Myocardial Infarction*; Humans

  • Source: European heart journal [Eur Heart J] 2024 Jul 12; Vol. 45 (27), pp. 2360-2361.Publisher: Oxford University Press Country of Publication: England NLM ID: 8006263 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction.

  • Authors : Packer M; Baylor Heart and Vascular Institute, Dallas, TX, USA.; Imperial College, London, UK.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Heart Failure*/Heart Failure*/Heart Failure*/drug therapy ; Stroke Volume*/Stroke Volume*/Stroke Volume*/physiology

  • Source: European heart journal [Eur Heart J] 2024 Jul 09; Vol. 45 (25), pp. 2186-2196.Publisher: Oxford University Press Country of Publication: England NLM ID: 8006263 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

SGLT2 inhibitors: a therapy for everybody but not for anything?

  • Authors : Villaschi A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 4, 20072 Pieve Emanuele, Milan, Italy.; Cardio Center, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni, 56, 20089 Rozzano, Milan, Italy.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

  • Source: European journal of preventive cardiology [Eur J Prev Cardiol] 2024 May 11; Vol. 31 (7), pp. 768-769.Publisher: Oxford University Press Country of Publication: England NLM ID: 101564430 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Sodium-glucose cotransporter-2 inhibitors had a significant association with less atrial fibrillation.

  • Authors : Xiao Y; Department of Dermatology, The People's Hospital of Longhua, Shenzhen City, Guangdong Province, 518109, China.; Liu C

Subjects: Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects

  • Source: European journal of preventive cardiology [Eur J Prev Cardiol] 2024 May 11; Vol. 31 (7), pp. e53-e54.Publisher: Oxford University Press Country of Publication: England NLM ID: 101564430 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Does it matter how we measure urinary creatinine in patients taking SGLT2 inhibitors?

  • Authors : Bock F; Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.; Isermann B

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Creatinine*/Creatinine*/Creatinine*/urine

  • Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2024 Apr 26; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  241 results for ""Sodium-Glucose Transporter 2 Inhibitors""